一名接受A型肉毒杆菌毒素治疗的新冠肺炎感染男性出现肢端坏死。

Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A.

作者信息

Schjødt Mette Soelberg, Bech Rikke, Braae Olesen Anne

机构信息

Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Case Rep Dermatol. 2021 Dec 27;13(3):568-573. doi: 10.1159/000520589. eCollection 2021 Sep-Dec.

DOI:10.1159/000520589

PMID:35111009

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8787540/

Abstract

COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox injection as a new and improving treatment for acral necroses due to COVID-19.

摘要

2019冠状病毒病（COVID-19）与肢端缺血和指端坏死有关。肢端缺血以及指端或肢端坏死的标准治疗包括持续使用血管扩张剂和抗凝剂进行治疗。然而，这些治疗方法并不总能有效避免坏死的进展，在最坏的情况下可能导致截肢。在此，我们报告一例病例，其中指间注射肉毒杆菌毒素（A型肉毒毒素）阻断神经索阻止了由COVID-19引起的潜在血管病变导致的肢端坏死的进展。此外，肉毒杆菌毒素注射在2周内消除了受影响肢端区域的炎症。这是首例表明肉毒杆菌毒素注射可作为COVID-19所致肢端坏死的一种新的、有效的治疗方法的病例报告。